Patents by Inventor Oisun JUNG

Oisun JUNG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Syndecan peptides and polypeptides as inhibitors of vascular endothelial growth factor receptor-2 (VEGFR2) and very late antigen-4 (VLA-4)
    Patent number: 10485849
    Abstract: Peptides from syndecan 1 and methods of use therefor are described. These peptides can inhibit very late antigen-4 (VLA-4) interaction with vascular endothelial growth factor-2 (VEGFR2), thereby preventing tumor cell growth and tissue invasion.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: November 26, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Alan Rapraeger, Oisun Jung
  • SYNDECAN PEPTIDES AND POLYPEPTIDES AS INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 (VEGFR2) AND VERY LATE ANTIGEN-4 (VLA-4)
    Publication number: 20180169185
    Abstract: The disclosure provides for peptides from syndecan 1 and methods of use therefor. These peptides can inhibit VLA-4 interaction with VEGFR2, thereby preventing tumor cell growth and tissue invasion.
    Type: Application
    Filed: January 29, 2018
    Publication date: June 21, 2018
    Inventors: Alan RAPRAEGER, Oisun JUNG
  • Peptides that inhibit syndecan-1 activation of VLA-4 and IGF-1R
    Patent number: 9963498
    Abstract: A fusion peptides with sequences derived from the extracellular domain of syndecan-1 that inhibits VLA-4 and IGF-1R signaling are disclosed. The fusion peptides include an IGF-1R-binding segment having the amino acid sequence LPAGEGPKEGEAVVLPEVEPGLTAREQ (SEQ ID NO:1) and a VLA-4-binding segment having the amino acid sequence sequence DFTFETSGENTA (SEQ ID NO:2).
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: May 8, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Alan C. Rapraeger, DeannaLee M. Beauvais, Oisun Jung
  • Peptides that Inhibit Syndecan-1 Activation of VLA-4 and IGF-1R
    Publication number: 20180086813
    Abstract: A fusion peptides with sequences derived from the extracellular domain of syndecan-1 that inhibits VLA-4 and IGF-1R signaling are disclosed. The fusion peptides include an IGF-1R-binding segment having the amino acid sequence LPAGEGPKEGEAVVLPEVEPGLTAREQ (SEQ ID NO:1) and a VLA-4-binding segment having the amino acid sequence sequence DFTFETSGENTA (SEQ ID NO:2).
    Type: Application
    Filed: August 18, 2017
    Publication date: March 29, 2018
    Inventors: Alan C. Rapraeger, DeannaLee M. Beauvais, Oisun Jung
  • Syndecan peptides and polypeptides as inhibitors of vascular endothelial growth factor receptor-2 (VEGFR2) and very late antigen-4 (VLA-4)
    Patent number: 9878007
    Abstract: Peptides derived from amino acid residues 210 to 240 of human syndecan 1 and methods of use of such peptides are described. These peptides can inhibit activation of ?4?1 integrin (also known as very late antigen-4, VLA-4), and can inhibit engagement of VLA-4 with vascular endothelial growth factor receptor-2 (VEGFR2), thereby preventing tumor cell growth and tissue invasion.
    Type: Grant
    Filed: February 15, 2016
    Date of Patent: January 30, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Alan Rapraeger, Oisun Jung
  • SYNDECAN PEPTIDES AND POLYPEPTIDES AS INHIBITORS OF VEGFR2 AND VLA-4
    Publication number: 20160256523
    Abstract: The disclosure provides for peptides from syndecan 1 and methods of use therefor. These peptides can inhibit VLA-4 interaction with VEGFR2, thereby preventing tumor cell growth and tissue invasion.
    Type: Application
    Filed: February 15, 2016
    Publication date: September 8, 2016
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Alan RAPRAEGER, Oisun JUNG